Senseonics Holdings

Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a glucose monitoring device which includes sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Senseonics achieves FDA milestone with Eversense 365, focuses on growth

Senseonics had a pivotal quarter with FDA approval of Eversense 365, driving positive feedback and strong adoption.
Financially, the company reported Q3 net revenue of $4.3 million with a gross loss of $4.1 million, focusing on cost reduction.
Efforts to reduce operating expenses and extend cash runway aim to address financial challenges and enhance stability.
With opportunities to accelerate sales, improve diabetes management, and expand market reach, Senseonics is poised for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings, Inc. (NYSE:SENS) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET

Senseonics Holdings, Inc. (SENS) Q4 2023 Earnings Call Transcript

Senseonics Holdings (SENS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.01 per share a year ago.

Senseonics Holdings (SENS) Reports Q4 Loss, Tops Revenue Estimates

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2023. Recent Highlights & Accomplishments: Generated revenue of $8.0 million in the fourth quarter of 2023, representing growth of 44% compared to the prior yea.

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2023 financial results after market close on Thursday, February 29, 2024. Management will hold a conference call to review the Company's fourth quarter and full year 2023 p.

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinatio.

Medicare Coverage Significantly Expanded for the Eversense E3 CGM System

The decision is further recognition of Eversense as an important option for people with diabetes PARSIPPANY, N.J. , Feb. 12, 2024 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM

TOKYO--(BUSINESS WIRE)--PHC Holdings Corporation (TSE: 6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care, a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of Pre.

PHC Holdings Corporation and Senseonics Announce Appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care

Grab Holdings Ltd

Nokia

Some of the best penny stocks are primed to reach new heights in the first quarter of this year. I expect investor's risk tolerance to increase amid a broadening market breadth as the valuations of mega caps and large caps may be too rich to be sufficiently attractive.

3 Penny Stocks to Watch for Explosive Growth in Q1 2024

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational and financial business updates. Recent Highlights & Accomplishments: Generated preliminary unaudited fourth quarter revenue of approximately $8.0 million, and unaudited full year 2023 total revenue of approximately.

Senseonics Holdings, Inc. Announces Business Updates

Agile Therapeutics

SoundHound AI Inc

Stem, Inc

Whether you subscribe to the idea that penny stocks are always a buy or determine your strategy based on broader market conditions, chances are that cheap stocks are on your watch list. While these sweeping market trends might not influence low-priced equities, it's important to understand what's going on in the stock market today.

Top Penny Stocks To Buy Now? 4 To Watch Under $4

Ardelyx

Opendoor

Plug Power

The Beauty Health Company

Exploring the world of penny stocks offers exciting investment opportunities, but it requires astute strategies to identify real winners. In this update, we delve into essential techniques for finding penny stocks to buy and a list of cheap stocks to watch today.

5 Hot Penny Stocks To Watch Today

Senseonics Holdings, Inc. (NYSE:SENS ) Q3 2023 Earnings Call Transcript November 9, 2023 4:30 PM ET Company Participants Trip Taylor - IR Tim Goodnow - President and CEO Rick Sullivan - CFO Mukul Jain - COO Conference Call Participants Marie Thibault - BTIG Jayson Bedford - Raymond James Operator Good day and welcome to the Senseonics Third Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode.

Senseonics Holdings, Inc. (SENS) Q3 2023 Earnings Call Transcript

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended September 30, 2023. Recent Highlights & Accomplishments: Generated revenue of $6.1 million in the third quarter of 2023 Announced the last patient completion of the 365-day ENHANCE Pivota.

Senseonics Holdings, Inc. Reports Third Quarter 2023 Financial Results

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2023 Healthcare Conference, taking place in New York, NY. Management is scheduled to present on Tuesday, November 14, 2023 from 4:45pm to 5:15pm ET. Interested parties may access a live.

Senseonics Holdings, Inc. to Participate in the Stifel 2023 Healthcare Conference

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2023 financial results after market close on Thursday, November 9, 2023. Management will hold a conference call to review the Company's third quarter 2023 performance starting at 4:30 p.m.

Senseonics Holdings, Inc Schedules Third Quarter 2023 Earnings Release and Conference Call for November 9, 2023 at 4:30 p.m. Eastern Time

PARSIPPANY, N.J. & GERMANTOWN, Md.--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, have launched a new U.S. advertising and marketing campaign for Eversense® E3 CGM System. ‘The CGM for Real Life' campaign is designed to significantly drive awareness.

Ascensia Diabetes Care and Senseonics Announce ‘The CGM for Real Life' Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the completion of the ENHANCE Pivotal Clinical Study adult cohort following the recently completed 365-day visit for the final study patient. “We are pleased that all patients have completed the testing for the adult arm of the EN.

Senseonics Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Management is scheduled to present on Thursday, September 21, 2023 from 11:30 a.m. to 11:55 a.m. ET. Interested parties.

Senseonics Holdings, Inc. to Participate in the Gilmartin Group Emerging Growth Company Showcase

Aurora Cannabis

Asensus Surgical

Better Home & Finance Holding Co

Inpixon

Nektar Therapeutics

Nemaura Medical

Novo Integrated Sciences, Inc.

Founder SPAC

Synaptogenix

Let's be honest – penny stocks priced at less than a buck hold an irresistible appeal. Even a small investment could potentially lead to insane returns.

Best Penny Stocks To Buy Now? 10 Under $1 To Watch

Penny stocks priced under $1 per share have attracted a dedicated following among traders seeking massive returns. While penny stocks are inherently high-risk investments, the potential reward with these low-priced shares is exponentially higher compared to traditional blue chip stocks.

Best Penny Stocks To Buy Now? 7 Under $1 To Watch

Hercules Capital

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has entered into a $50 million loan facility with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”). The company also announced it drew down $25 million upon the transaction closing. “This loan facility provides increased f.

Senseonics Holdings, Inc. Enters Into $50 Million Loan Facility With Hercules Capital

Globalstar

P3 Health Partners Inc

The allure of penny stocks is undeniable. Their low price point, combined with the potential for high returns, makes them a tantalizing option for investors.

3 Top Penny Stocks To Buy Now According To Insiders

Senseonics Holdings (SENS) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.

Senseonics Holdings (SENS) Reports Q2 Loss, Misses Revenue Estimates

Senseonics Holdings, Inc. (NYSE:SENS ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Philip Taylor - IR Tim Goodnow - President and CEO Rick Sullivan - CFO Conference Call Participants Colin Clark - Stifel Sam Eiber - BTIG Jayson Bedford - Raymond James Operator Good day, and welcome to the Senseonics Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

Senseonics Holdings, Inc. (SENS) Q2 2023 Earnings Call Transcript

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended June 30, 2023. Recent Highlights & Accomplishments: Generated revenue of $4.1 million in the second quarter of 2023 Submitted an application to the FDA for an iCGM designation for the Eve.

News for Senseonics Holdings Stock (SENS)